Wright-Nadkarni M, Moscato EL, Stanek JR, Schaefer MR, Gerhardt CA, Ashley DM, Baxter PA, N S, Dorris K, Fisher MJ, Hummel TR, Hwang EI, Gass D, Leary SES, Pillay-Smiley N, Plant-Fox AS, Murala M, Mikael L, Dewire-Schottmiller M, Drissi R, Fouladi M, Lazow MA. Longitudinal Caregiver- and Patient-reported Health-related Outcomes of Pediatric Patients with High-grade Gliomas Enrolled on CONNECT1701 and CONNECT1702. Neuro-Oncology Practice. 2026;:10.1093/nop/npag102
Chandramohan V, Herndon JE, Barnwal A, Ayasoufi K, Yan W, Stevenson K, Bowie ML, Brown MC, Nair SK, Gromeier M, Randazzo D, Peters KB, Johnson MO, McLendon RE, Landi D, Sampson JH, Pastan IH, Friedman AH, Friedman HS, Ashley DM, Bigner DD, Desjardins A. EGFR-targeted antibody−toxin conjugate in recurrent glioma: a phase 1 trial. Nature Medicine. 2026;:10.1038/s41591-026-04715-w
Chowdhury T, Tesileanu CMS, Kocakavuk E, Johnson KC, Lee JH, Erson-Omay Z, Heo C, Aldape K, Amin SB, Anderson KJ, Ashley DM, Barthel FP, Barnholtz-Sloan JS, Brat DJ, Brodbelt AR, Castro AV, Claus EB, Connelly JM, Costello JF, Datta I, Elliott C, Finocchiaro G, French PJ, Gan HK, Garofano L, Ghospurkar PL, Golebiewska A, Gundla PS, Hermes B, Hong C, Hoogstrate Y, Horbinski C, Huse JT, Iavarone A, Karadag C, Khasraw M, Kouwenhoven MCM, LaViolette PS, Li K, Lowman A, McCortney K, Moon H-E, Sanai N, Nasrallah MP, Ng HK, Ormond DR, Kwan B, Padovan M, Paek SH, Poisson LM, Puri S, Shen E, Mehta S, Sloan AE, Vallentgoed WR, Van Meir EG, Vaubel R, Wade TE, Walenkamp AME, Watts C, Weiss T, Weller M, Wesseling P, Westcott K, Westerman BA, Ye GY, Alfred Yung WK, Varn FS, Verhaak RGW. Divergent genomic evolution in astrocytomas and oligodendrogliomas. Nature. 2026;:10.1038/s41586-026-11150-x
Teraishi A, Sanvito F, Raymond C, Cho NS, Norris J, Gandhi S, Cohen AR, Hafizka Y, Luo A, Sim H-W, Wachsmuth LP, Yip S, Koh E-S, Hall M, Ashley DM, Rosenthal MA, Hovey EJ, Gan HK, Johnson MO, Barnes EH, Simes JR, Lwin Z, Khasraw M, Salamon N, Cloughesy TF, Ellingson BM. Automated imaging response evaluation system: Prototype software tool for standardized radiographic response assessment in glioblastoma clinical trials. Neuro-Oncology Practice. 2026;13(5):10.1093/nop/npag039
Vaios EJ, Wimberly C, Sim HW, Barnes E, Koh ES, Yip S, Hall M, Herrgott G, Noushmehr H, Ayasoufi K, Batich K, Ashley DM, Floyd SR, Shih HA, Sulman EP, Simes J, Reitman ZJ, Walsh K, Hu B, Khasraw M. A Blood-based DNA Methylation Signature for Non-invasive Diagnosis and Prediction of Clinical Outcomes in Patients with Glioblastoma Enrolled on the Phase II Randomized VERTU Trial. International Journal of Radiation Oncology • Biology • Physics. 2026;126(1):10.1016/j.ijrobp.2026.06.520
Owens E, Hotchkiss K, Brown M, Threatt S, Low J, Anand M, Goldston M, Johnson M, Bradbury C, Herndon J, Grant G, Ashley D, Patel A, Desjardins A, Khasraw M. Oncolytic HSV-1 Encoding IL-12 and Anti-PD-1 Reprograms CNS Immunity: Open-Label Study of MVR-C5252 for Safety, Tolerability, and Efficacy (PuMP) 2259418. The Journal of Immunology. 2026;215(Supplement_1):10.1093/jimmun/vkag141.710
Louw J, Zhang K, Corcoran A, Owens E, Jepson J, Conejo-Garcia J, Ashley D, Mirchia K, Raleigh D, Khasraw M. Spatial Transcriptomics Reveals Immune Remodeling in Recurrent Oligodendroglioma 2259684. The Journal of Immunology. 2026;215(Supplement_1):10.1093/jimmun/vkag141.763
Hotchkiss K, Norberg P, Buckley E, Owens E, Ayasoufi K, Threatt S, Low J, Shoaf M, Goldston M, Batich K, Johnson M, Herndon J, Nair S, Weinhold K, Friedman H, Ashley D, Desjardins A, Sampson J, Khasraw M. A universal CD4 epitope enhances cytotoxic T-cell priming and memory in glioblastoma peptide vaccination 2257077. The Journal of Immunology. 2026;215(Supplement_1):10.1093/jimmun/vkag141.388
Young E, Govender D, Waldeck K, Gottardo N, Strong R, Kinross K, Carr M, Jones J, Wong L, Ziegler D, Hansford J, Michael M, Tremblay C, Rudkin A, Winstanley M, Desai J, Ashley D, Cain J, Wood P. ID #672 A phase II study of continuous low dose panobinostat in paediatric patients with atypical teratoid rhabdoid tumours (ATRT).Neuro-Oncology Pediatrics. 2026;2(Supplement_1):10.1093/neuped/wuag026.271
Minor M, Zhang J, Elkholi R, Dewey J, Patel M, Savelli A, Johnson M, Batich K, Low J, Shoaf M, Khasraw M, DesJardins A, Friedman H, Ashley D, Calabrese E, Peters K. Response to Next Intervention After Off-label Ivosidenib Treatment Failure in Patients With Mutant IDH Low Grade Glioma (S28.003). Neurology. 2026;106(11_Supplement_1):10.1212/wnl.0000000000216670
